Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer. 

The biggest cohort of patients with prostate cancer has not led to the discovery of biomarkers for advanced disease. Primary metastatic tumors need to be studied in more detail to determine the evolution of this disease. 

It would also be interesting to identify markers of progression for patients with advanced disease within primary tumors by comparing the genomic alterations across lesions.

Videos

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Significance of Analyzing Gene Mutations in Prostate Cancer 

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

A mutational significance analysis was conducted to detect novel genes and pathways in 918 patients with prostate cancer. The goal of the study was to redefine the genomic landscape of prostate cancer, says Armenia.

Twenty-three novel genes were identified that were not previously found to be significantly mutated in prostate cancer, but were recurrent in other cancers, such as 

 in breast cancer. Frequent truncating mutations in key regulators of the SWI/SNF complex such as 

 were also identified, as well as an enrichment in splicing pathway alterations in 

According to Armenia, this analysis provides a broader persepective of pathways to consider in the treatment of patients with prostate cancer.

View more from the 2017 Genitourinary Cancers Symposium

Joshua Armenia, PhD

Articles

Significance of Analyzing Gene Mutations in Prostate Cancer

Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer